Green Thumb Industries Posts 7% Revenue Growth Amid Federal Cannabis Rescheduling
Event summary
- Q1 2026 revenue reached $300.2M, up 7.4% YoY, driven by adult-use sales in Minnesota and growth in Connecticut and Florida.
- Normalized EBITDA was $93.5M (31.2% of revenue), with cash flow from operations at $76.0M.
- Repurchased 13.4M shares year-to-date for $77.7M, totaling $200M since September 2023.
- Conditionally awarded a Texas Compassionate Use Program license for vertically integrated operations.
- Submitted DEA registration applications for state-licensed medical cannabis operations post-federal rescheduling.
The big picture
Green Thumb's Q1 2026 results reflect steady growth in a maturing cannabis market, bolstered by federal rescheduling. The company's strategic focus on share repurchases and expansion into new markets like Texas underscores its confidence in long-term industry tailwinds. However, sustained profitability will depend on navigating competitive pressures and optimizing operational margins.
What we're watching
- Regulatory Tailwinds
- How federal rescheduling to Schedule III will impact Green Thumb's operational flexibility and tax relief.
- Market Competition
- Whether Green Thumb can sustain growth amid price compression and increased competition in key markets.
- Capital Efficiency
- The pace at which share repurchases will continue and their effect on shareholder value.
Related topics